On March 20, 2026, Apimeds Pharmaceuticals US, Inc. removed four directors and appointed three new ones, along with a new CEO, as part of concerns over a merger with MindWave Innovations. The company is also expanding into new business initiatives and intends to pursue joint ventures in the cosmetics and e-commerce markets.